Monopar Therapeutics (NASDAQ:MNPR) Now Covered by BTIG Research

Key Points

• BTIG Research has initiated coverage on Monopar Therapeutics (NASDAQ:MNPR), assigning a "buy" rating and setting a price target of $87.00, indicating a potential upside of 109.74% from its previous close.
• Several analysts have provided ratings for Monopar Therapeutics, with one "Strong Buy," seven "Buy," and one "Hold," resulting in an average rating of "Buy" and a consensus target price of $71.75.
• Monopar Therapeutics reported an EPS of ($0.35) for the latest quarter, beating analysts’ expectations, while its shares were recently down 6.2% to open at $41.48.

BTIG Research began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Free Report) in a report released on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $87.00 price target on the stock.

A number of other equities analysts also recently issued reports on the company. HC Wainwright assumed coverage on Monopar Therapeutics in a research report on Tuesday, August 26th. They set a "buy" rating and a $70.00 price objective for the company. Wall Street Zen upgraded Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Oppenheimer began coverage on Monopar Therapeutics in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $77.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $74.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $60.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $71.75.

Monopar Therapeutics Stock Performance

Shares of MNPR traded up $1.55 during mid-day trading on Tuesday, reaching $49.22. 22,352 shares of the company were exchanged, compared to its average volume of 37,816. Monopar Therapeutics has a 52 week low of $3.33 and a 52 week high of $54.30. The stock has a market capitalization of $303.69 million, a PE ratio of -14.78 and a beta of 1.20. The business has a 50 day simple moving average of $39.33 and a two-hundred day simple moving average of $36.93.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.12. On average, analysts predict that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Buying and Selling

In other Monopar Therapeutics news, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the transaction, the director owned 11,486 shares in the company, valued at approximately $459,440. This represents a 43.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the chief executive officer owned 73,472 shares in the company, valued at approximately $2,938,880. The trade was a 18.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,504 shares of company stock valued at $1,700,160 over the last 90 days. Company insiders own 20.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Monopar Therapeutics in the second quarter valued at approximately $80,000. Affinity Asset Advisors LLC increased its position in shares of Monopar Therapeutics by 8.9% during the second quarter. Affinity Asset Advisors LLC now owns 67,500 shares of the company's stock valued at $2,415,000 after acquiring an additional 5,500 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in shares of Monopar Therapeutics during the second quarter valued at approximately $104,000. Rhumbline Advisers purchased a new stake in shares of Monopar Therapeutics during the second quarter valued at approximately $209,000. Finally, JPMorgan Chase & Co. increased its position in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after acquiring an additional 1,821 shares during the last quarter. Institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.